NasdaqCM:KOOL

Stock Analysis Report

Executive Summary

Cesca Therapeutics Inc. develops, commercializes, and markets a range of automated technologies for cell-based therapies in the United States, China, rest of Asia, Europe, and internationally.

Snowflake

Fundamentals

Mediocre balance sheet with limited growth.


Similar Companies

Share Price & News

How has Cesca Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-17.7%

KOOL

1.7%

US Medical Equipment

2.3%

US Market


1 Year Return

32.4%

KOOL

10.1%

US Medical Equipment

5.6%

US Market

Return vs Industry: KOOL exceeded the US Medical Equipment industry which returned 10.1% over the past year.

Return vs Market: KOOL exceeded the US Market which returned 5.6% over the past year.


Shareholder returns

KOOLIndustryMarket
7 Day-17.7%1.7%2.3%
30 Day15.8%-1.7%-1.0%
90 Day50.7%-1.7%-0.7%
1 Year32.4%32.4%11.0%10.1%7.9%5.6%
3 Year-83.3%-83.3%70.4%65.2%45.6%36.3%
5 Year-97.8%-97.8%128.5%103.2%65.8%47.6%

Price Volatility Vs. Market

How volatile is Cesca Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Cesca Therapeutics undervalued compared to its fair value and its price relative to the market?

2.1x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate KOOL's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate KOOL's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: KOOL is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: KOOL is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate KOOL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: KOOL is good value based on its PB Ratio (2.1x) compared to the US Medical Equipment industry average (3.7x).


Next Steps

Future Growth

How is Cesca Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

32.1%

Forecasted annual revenue growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if KOOL's forecast earnings growth is above the savings rate (2.7%).

Earnings vs Market: Insufficient data to determine if KOOL's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: KOOL's revenue (32.1% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: KOOL's revenue (32.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if KOOL's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Cesca Therapeutics performed over the past 5 years?

-16.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: KOOL is unprofitable, and losses have increased over the past 5 years at a rate of -16.7% per year.

Accelerating Growth: Unable to compare KOOL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: KOOL is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).


Return on Equity

High ROE: KOOL has a negative Return on Equity (-208.92%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: KOOL is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: KOOL is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Cesca Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: KOOL's short term assets ($9.9M) exceeds its short term liabilities ($6.5M)

Long Term Liabilities: KOOL's short term assets (9.9M) exceeds its long term liabilities (3.6M)


Debt to Equity History and Analysis

Debt Level: KOOL's debt to equity ratio (37%) is considered satisfactory

Reducing Debt: Insufficient data to determine if KOOL's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: KOOL has a high level of physical assets or inventory.

Debt Coverage by Assets: KOOL's debt is covered by short term assets (assets are 4.101120x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: KOOL has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: KOOL has less than a year of cash runway if free cash flow continues to grow at historical rates of 8.1% each year.


Next Steps

Dividend

What is Cesca Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate KOOL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate KOOL's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if KOOL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if KOOL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of KOOL's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Cesca Therapeutics's salary, the management and board of directors tenure and is there insider trading?

2.4yrs

Average management tenure


CEO

Chris Xu (48yo)

2.9yrs

Tenure

US$653,000

Compensation

Dr. Xiaochun Xu, also known as Chris, M.B.A. Ph.D., is the Founder, Chairman and Chief Executive Officer of Boyalife Group since July 2009. Dr. Xu has been the Chairman of Board and Chief Executive Officer ...


CEO Compensation Analysis

Compensation vs. Market: Chris's total compensation ($USD653.00K) is about average for companies of similar size in the US market ($USD493.00K).

Compensation vs Earnings: Chris's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

2.4yrs

Average Tenure

48yo

Average Age

Experienced Management: KOOL's management team is considered experienced (2.4 years average tenure).


Board Age and Tenure

2.9yrs

Average Tenure

49yo

Average Age

Experienced Board: KOOL's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Phil Coelho (75yo)

    Chief Technology Officer

    • Tenure: 2.3yrs
    • Compensation: US$240.75k
  • Chris Xu (48yo)

    Chairman of the Board

    • Tenure: 2.9yrs
    • Compensation: US$653.00k
  • Jim Xu (48yo)

    Director

    • Tenure: 2.9yrs
    • Compensation: US$130.00k
  • Jeff Cauble (46yo)

    Principal Financial & Accounting Officer

    • Tenure: 2.6yrs
    • Compensation: US$209.00k
  • Haihong Zhu

    President of ThermoGenesis

    • Tenure: 0yrs

Board Members

  • Russell Medford (64yo)

    Director

    • Tenure: 2.7yrs
    • Compensation: US$47.00k
  • Mark Westgate (49yo)

    Director

    • Tenure: 2.4yrs
    • Compensation: US$38.50k
  • Solomon Hamburg

    Member of Clinical & Scientific Advisory Board

    • Tenure: 5.4yrs
  • Chris Xu (48yo)

    Chairman of the Board

    • Tenure: 2.9yrs
    • Compensation: US$653.00k
  • Lars Norgren

    Member of Clinical Advisory Board

    • Tenure: 3.6yrs
  • Jim Xu (48yo)

    Director

    • Tenure: 2.9yrs
    • Compensation: US$130.00k
  • Jeff Thomis (73yo)

    Director

    • Tenure: 2.8yrs
    • Compensation: US$42.00k

Company Information

Cesca Therapeutics Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Cesca Therapeutics Inc.
  • Ticker: KOOL
  • Exchange: NasdaqCM
  • Founded: 1986
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$12.251m
  • Shares outstanding: 2.42m
  • Website: https://www.cescatherapeutics.com

Number of Employees


Location

  • Cesca Therapeutics Inc.
  • 2711 Citrus Road
  • Rancho Cordova
  • California
  • 95742
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
KOOLNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJun 1987
THRNDB (Deutsche Boerse AG)YesCommon StockDEEURJun 1987
THRPMUN (Boerse Muenchen)YesCommon StockDEEURJun 1987

Biography

Cesca Therapeutics Inc. develops, commercializes, and markets a range of automated technologies for cell-based therapies in the United States, China, rest of Asia, Europe, and internationally. The company  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/16 23:43
End of Day Share Price2019/10/16 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.